Melphalan Culprit or Confounder in Acute Encephalopathy during Autologous Hematopoietic Stem Cell Transplantation?

Por Alayón-Laguer, Diógenes, Alsina, Melissa, Ochoa-Bayona, Jose L., Ayala, Ernesto
Publicado em 2012

An open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myeloma

Por Nishihori, Taiga, Baz, Rachid, Shain, Kenneth, Kim, Jongphil, Ochoa-Bayona, Jose L., Yue, Binglin, Sullivan, Daniel, Dalton, William, Alsina, Melissa
Publicado no Eur J Haematol (2015)

Phase II Study of CD4(+)-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting

Por Kharfan-Dabaja, Mohamed A., Anasetti, Claudio, Fernandez, Hugo F., Perkins, Janelle, Ochoa-Bayona, Jose L., Pidala, Joseph, Perez, Lia E., Ayala, Ernesto, Field, Teresa, Alsina, Melissa, Nishihori, Taiga, Locke, Frederick, Pinilla-Ibarz, Javier, Tomblyn, Marcie
Publicado no Biol Blood Marrow Transplant (2013)

Bortezomib salvage followed by a phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma

Por Nishihori, Taiga, Alekshun, Todd J., Shain, Kenneth, Sullivan, Daniel M., Baz, Rachid, Perez, Lia, Pidala, Joseph, Kharfan-Dabaja, Mohamed A., Ochoa-Bayona, Jose L, Fernandez, Hugo F, Yarde, Danielle N., Oliveira, Vasco, Fulp, William, Han, Gang, Kim, Jongphil, Chen, Dung-Tsa, Raychaudhuri, Jyoti, Dalton, William, Anasetti, Claudio, Alsina, Melissa
Publicado em 2012